Rationale: Acute ST-segment elevation myocardial infarction (STEMI) is a rare complication of acute ischemic stroke (AIS) during thrombolytic therapy. We report a case of STEMI occurring 40 minutes after thrombolytic therapy for AIS and discuss the possible mechanisms and therapeutic approaches.

Patient Concerns: A 87-year-old woman with a history of arterial hypertension was admitted for acute onset of right-sided limb weakness 2 hours before arrival at the emergency department. Forty minutes after intravenous recombinant tissue plasminogen activator (i.v. rtPA) administration for AIS, STEMI occurred (signaled by a third-degree atrioventricular block).

Diagnoses: The diagnoses were AIS and STEMI. Coronary angiography confirmed right coronary artery occlusion.

Interventions: Four hours after the onset of STEMI, stenting was performed, normalizing the coronary blood flow.

Outcomes: The patient died 2 days thereafter because of persistent cardiogenic shock.

Lessons: Our case is remarkable owing to the unusually early (<1 hour) occurrence of STEMI after i.v. rtPA administration. A third-degree atrioventricular block after thrombolysis for AIS could signal a STEMI onset. New and ongoing trials are assessing whether adjunct administration of direct thrombin inhibitors of rtPA in the first 24 hours after thrombolysis for AIS can prevent early recurrent ischemic events.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320080PMC
http://dx.doi.org/10.1097/MD.0000000000013347DOI Listing

Publication Analysis

Top Keywords

thrombolytic therapy
12
st-segment elevation
8
myocardial infarction
8
acute ischemic
8
ischemic stroke
8
ais stemi
8
acute
5
stemi
5
early st-segment
4
elevation acute
4

Similar Publications

Background: Correct identification of those patients presenting with an acute vestibular syndrome (AVS) or an acute imbalance syndrome (AIS) that have underlying posterior-circulation stroke (PCS) and thus may benefit from revascularization (intravenous thrombolysis (IVT), endovascular therapy (EVT)) is important. Treatment guidelines for AVS/AIS patients are lacking. We reviewed the evidence on acute treatment strategies in AVS/AIS focusing on predictors for IVT/EVT and outcome.

View Article and Find Full Text PDF

Introduction: Pleural infections are a significant cause of mortality. Intrapleural fibrinolytic therapy (IPFT) utilising alteplase and dornase is a treatment option for patients unsuitable for surgery. The optimal dose of alteplase is unknown, and factors affecting treatment success in an Asian population are unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Allergic reactions and angioedema are significant conditions in emergency care, affecting patient management.
  • A study evaluated maximum lysis (ML) using thromboelastometry in patients with immunologic reactions, measuring ML at admission and two hours later.
  • Results showed that patients still experiencing symptoms after two hours had higher ML than those who were asymptomatic, indicating a potential link between symptom persistence and changes in ML.
View Article and Find Full Text PDF

Patients at high risk of deep vein thrombosis are recommended to undergo lower-extremity ultrasonography to screen for pulmonary embolism (PE); however, there are few reports on whether this can effectively reduce the occurrence of fatal pulmonary embolism (FPE). This study aimed to assess the risk factors associated with PE and to investigate whether perioperative ultrasound screening of lower extremity veins in orthopedic patients can effectively reduce the incidence of FPE. We enrolled 137 patients with PE who underwent orthopedic surgery between 2013 and 2020.

View Article and Find Full Text PDF

Fibrinolytic enzymes are promising in treating cardiovascular diseases due to their capacity to dissolve blood clots. The fibrinolytic enzyme from Arthrospira platensis (FEAP) was purified by ion exchange chromatography to investigate its ability to activate plasminogen, as well as its thrombolytic and fibrinogenolytic potential. Subsequently, two different cytotoxic assays (MTT and NR) and hemolysis test were performed to evaluate FEAP's safety.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!